After the onset of myocardial infarction, extensive coronary thrombus and oxygen supply insufficiency lead to severe myocardial damage and heart failure. Recently, ultrasound-irradiated phase-change nanoparticles have been recognized for their cardiovascular thrombolysis potential. Therefore, we sought to establish a novel treatment method using hydrogen peroxide (H₂O₂)/perfluoropentane (PFP) phase-change nanoparticles with low-intensity focused ultrasound (LIFU) for the simulation of acute coronary thrombolysis and myocardial preservation. There were three groups in our study: Group A consisted of phosphate-buffered saline (PBS) as the blank control, group B consisted of SonoVue microbubbles and group C consisted of H₂O₂/PFP phase-change nanoparticles. The H₂O₂/PFP phase-change nanoparticles were prepared using a double-emulsification process. The in vitro experiments were conducted in an artificial circulatory system connected to an LIFU system and dissolved oxygen detector. Thrombolysis efficiency and oxygen release efficiency were compared among the groups. H₂O₂/PFP nanoparticles with 3% H₂O₂ (average size: 456.7 ± 31.2 nm, charge: –37.5 ± 5.22 mV) was the optimal selection in group C because of the stable loading capacity and stable low-dose oxygen release efficiency in the in vitro experiments. Thrombolytic weight loss and loss rates in group C (322.0 ± 40.8 mg, 54.8 ± 5.7%) were significantly higher than those in group A (36.2 ± 18.1 mg, 5.5 ± 2.5%) and group B (91.0 ± 11.9 mg, 14.3 ± 2.4%) (p < 0.01). The innovative method using H₂O₂/PFP phase-change nanoparticles with LIFU exhibited high thrombolytic efficiency and stable low-flow oxygen supply in the artificial circulatory system, providing a solid experimental foundation for the establishment of a novel treatment method for acute myocardial infarction.

心肌梗死发作后，广泛的冠状动脉血栓和供氧不足导致严重的心肌损伤和心力衰竭。最近，超声辐照的相变纳米颗粒因其心血管血栓溶解潜力而被认可。因此，我们寻求建立一种新的治疗方法，使用过氧化氢 (H ₂ O ₂ )/全氟戊烷 (PFP​​) 相变纳米粒子与低强度聚焦超声 (LIFU) 模拟急性冠状动脉溶栓和心肌保存。我们的研究分为三组：A 组由磷酸盐缓冲盐水 (PBS) 组成作为空白对照，B 组由 SonoVue 微泡组成，C 组由 H ₂ O _{2 组成}/PFP 相变纳米粒子。H ₂ O ₂ /PFP 相变纳米颗粒采用双乳化工艺制备。在体外实验在连接到LIFU系统和溶解氧探测器人工循环系统进行。比较各组间溶栓效率和氧释放效率。含 3% H ₂ O _{2 的}H ₂ O ₂ /PFP 纳米颗粒（平均尺寸：456.7 ± 31.2 nm，电荷：–37.5 ± 5.22 mV）是 C 组中的最佳选择，因为它具有稳定的负载能力和稳定的低剂量氧气体外释放效率实验。C组溶栓体重减轻和丢失率（322.0±40.8mg，54.8±5.7%）显着高于A组（36.2±18.1mg，5.5±2.5%）和B组（91.0±11.9mg，14.3±2.5%） 2.4%) ( p < 0.01)。H ₂ O ₂ /PFP相变纳米粒子与LIFU的创新方法在人工循环系统中表现出高溶栓效率和稳定的低流量供氧，为建立急性心肌梗死新的治疗方法提供了坚实的实验基础.